As Evidence-Based Tumorigenic Role of Epstein-Barr Virus miR-BART1-3p in Neurological Tumors

Mohammad Karimzadeh¹, Alireza Tabibzadeh¹, Mohsen Moghoofei¹,², Saeedeh Abbasi³, Javid Sadri Nahand⁴, Farzin Sadeghi⁵, Mohammad Hadi Karbalaei Niya⁶, Hossein Keyvani³, Farah Bokharai-Salim³,⁴, Moein Esghaei⁵, Maryam Esghaei¹

Abstract

Introduction: Central nervous system tumors are a diverse group of tumors that account for 2% of all adult cancers and 17% of childhood malignancies. Several internal and external risk factors are involved in the development of this cancer such as viral infections. The aim of this study was to the determination of the EBV infection frequency and the expression level of miR-122 and miR-BART in CNS tumors samples. Methods: One hundred and thirty-eight fresh tissue sample (106 case and 32 control) was collected from CNS specimens. The presence of Epstein-Barr virus (EBV) DNA was examined by PCR assay and the expression level of miR-122 and miR-BART were evaluated by using real-time PCR assay in CNS tissue samples. Results: EBV DNA was detected in 17% (18 of 106) of tumors tissue samples and 6.4% (2 of 32) of control samples. according to results, there was a significant relationship between the presence of EBV-DNA with CNS tumors. Additionally, the expression level of miR-122 was significantly downregulated in the EBV-positive sample compared to that of the EBV-negative sample. Also, the level of EBV-BART1-3p expression was significantly higher in EBV-positive tumors samples than EBV-positive normal samples. Conclusion: The results of this study suggest that the EBV could change the condition of cancer cells by altering the expression of miR-122 and EBV-BART1-3p and maybe contribute to the development of cancer cells. However, the role of viral infections in CNS cancer requires further studies.

Keywords: Neurological tumors- epstein-barr virus- miR-BART- microRNA

Asian Pac J Cancer Prev, 22 (1), 257-266

Introduction

One of the most important malignancies in human is the central nervous system (CNS) tumors that constitute approximately 2% of all human adulthood cancers (Sadeghi et al., 2015a; He et al., 2016). Among the various types of CNS tumors including glioma, meningioma, and ependymoma arising from brain glial cells, meninges, and spinal cord, meningioma and glioblastoma are the most common type of these cancers (He et al., 2016; Sadeghi et al., 2015b; Xing et al., 2005). Although many studies have been done for detection of different tumors in CNS, the pathogenesis and etiology of many CNS tumors are still understood (Akhtar et al., 2018a; Kofman et al., 2011). It has been reported that some of the risk factors including ionizing radiation, radiation of cellular phones, electromagnetic fields, head injury, genetic polymorphisms, neuro-carcinogenic chemicals, atopic diseases and infectious disease (e.g. viral infections) play a critical role in the development of CNS tumors (Strojnik et al., 2017; Andrei et al., 2019; Khodabandehliou et al., 2019). In addition, several studies demonstrated which the genome of some viruses, such as Epstein-Barr virus (EBV), Human Cytomegalovirus, varicella-zoster virus, Human herpesvirus 6, herpes simplex virus type 1 and herpes simplex virus type 2, BK virus, Parvovirus B19 John Cunningham virus, and simian vacuolating virus 40 have been isolated frequently from CNS tumors samples (Bhattacharjee et al., 2018; Yi et al., 2009; Amon and Farrell, 2005; Ettemadi et al., 2017).

EBV is a common human, double-stranded DNA virus belonging to the Herpesviridae family. EBV is one of the most frequently contracted herpesviruses that about 95% of the adult human population infected. In 1964, EBV was identified as the first human oncovirus (Mui et al., 2019). Primary EBV infection commonly events during
Mohammad Karimzadeh et al
Asian Pacific Journal of Cancer Prevention, Vol 22

EBNA-2 and EBNA3C genes

and is associated with the B-cell malignancies development, including Burkitt’s lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphomas, central nervous system lymphomas, AIDS-associated lymphoma, post-transplant lymphoproliferative disorder (PTLD), as well as T-Cell and NK-Cell Lymphomas (Moghooefi et al., 2019).

MicroRNAs (miRNAs) are small non-coding RNAs (18–23 nucleotides) that recognize specific target mRNA sequences within the 3’ untranslated region and repress targeted gene expression through inducing mRNA degradation or translational suppression (Moghooefi et al., 2018, Sadri Nahand et al., 2019). Accumulating evidence has demonstrated that human miRNAs play an important role in several diseases such as viral infection disease and cancer (Rao et al., 2017). MiR-122 is the liver-specific miRNA and has a regulator role in liver development and in liver diseases. Furthermore, miR-122 operates as a tumors inhibitors gene or a deregulated factor in different types of malignancies including bladder, liver, gastric, and breast cancers (Wang et al., 2016, Sadri Nahand et al., 2019, Bandiera et al., 2015, Wang et al., 2014, Plaisance-Bonstaff and Renne, 2011, Zhang et al., 2018, Klinke et al., 2014). In addition to eukaryotes, miRNAs are also expressed in some of the viruses (EBV, HCMV, KSHV, HIV) (Cai et al., 2015). EBV encodes 44 mature miRNAs and 25 miRNA precursors from two regions of the genome: BamiHI fragment A rightward transcript (BART) and BamHI fragment H rightward reading frame 1 (BHRF1) (Strojnik et al., 2017). Noteworthy, previous researchers have shown that BART cluster miRNAs are effective in the process of tumors initiation (Leibovitch et al., 2016). It has been reported to EBV miRNAs play a critical role in immune evasion, latency maintenance, progression and development of the EBV-associated tumors through regulating both human and viral gene expression (Fonseca et al., 2015). Although in some studies EBV-DNA has been detected from glioblastoma and astrocytoma (Ai et al., 2012; Leibovitch et al., 2016; Fonseca et al., 2015; Zavala-Vega et al., 2017), the expression pattern of EBV miRNAs is not well evaluated yet. The aim of this study is to investigate the presence of the EBV and evaluating the expression level of miR-122 and miR-BART1-3p in CNS tumors specimens.

**Materials and Methods**

**Study population**

From January 2016 to November 2019, one hundred and three CNS tumors biopsy and blood samples were collected from patients who underwent surgical operations at The Neurosurgery Department of Rasoul-Akrham Hospital in Tehran, Iran. It should be noted that samples were obtained before chemotherapy. Furthermore, thirty-two CNS samples, as the control group, were collected from autopsy tissue samples, that were not related to the neurological disorders as a cause of death

Table 2. The CNS tumors type was confirmed as part of the routine histopathological examination in the Pathology Department of Rasoul Akrham Hospital. Case and control specimens were matched on sex and age. Before surgery operation time, except for one patient, all patients had a white blood cell count above 4,500 cells per microliter. Besides, none of the individuals received immunosuppressive drugs other than dexamethasone of 8 mg/m², which was prescribed to decrease pressure and swelling in the normal tissue around the tumors. For more details, see Table 1. This study was approved by the Ethical Committee of Iran University of Medical Sciences (Ethics approval number: IR.IUMS.FMD.REC.1397.085). Before entering the study, all participants were verbally informed of the aim and signed the consent form freely, according to the Declaration of Helsinki. All tissue samples were immediately placed into RNA later Stabilization Solution (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and were kept at -80°C until more process.

**DNA extraction**

Genomic DNA was extracted from all fresh tissue samples (N=106) by using the QIAamp DNA Mini Kit according to the manufacturer’s instructions (Qiagen, Germany). The quality and quantity of isolated DNA were specified with a Nanodrop spectrophotometer (Thermo Fisher Scientific, USA) at the end of the extraction procedure. The extracted DNA can be stored at −20°C prior to performing the polymerase chain reaction (PCR) reactions, if necessary.

**Polymerase chain reaction**

The presence of the EBV genome was detected by PCR with specific primers for EBNA3C and EBNA-2 genes (Ai et al., 2012; Kato et al., 2013). Briefly, The reaction mixture contained containing 100 ng to 1 μg of template DNA, Taq DNA Polymerase 2x Master Mix (Amplicon, Denmark), 10 nM of each primer, and water up to 25 μl and PCR assay was carried out by Mas-tercycler personal (Eppendorf, Hamburg, Germany) under the following program: one cycle of initial denaturation at 95°C for 5 min (EBNA3C), 3 min (EBNA-2) and; 35 cycles of denaturation at 95°C 45 s(EBNA3C), 15s (EBNA-2); hybridization at 56°C for 45s (EBNA3C), 63°C for15s (EBNA-2), extension at 72°C for 1min (EBNA3C), the 30s (EBNA-2), and finally elongation at 72°C for 10 min (EBNA3C), 1 min (EBNA-2).

**Real-time quantitative PCR**

The quantification of miR-122 and miR-BART1-3p expression levels were conducted by SYBR green quantitative PCR (qPCR) kit (Qiagen, Germany). Briefly, total RNAs were isolated from CNS tumors tissues and healthy control tissues by TRizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA), and PCR was performed by miScript SYBR Green PCR Kit (Qiagen, Valencia, CA; #218073), according to the manufacturer’s instructions. The qRT-PCR was performed in triplicate on an ABI PRISM 7000 (Applied Biosystems). The thermocycler conditions were as follows: 95°C for 2...
minutes, followed by 40 cycles of 94°C for 15 seconds, 60°C for 20 seconds, and 70°C for 25 seconds. The ΔΔCt values were utilized to 2−ΔΔCT method and U6 small nuclear RNA (as an internal control) were used to analysis of relative gene expression data.

**Statistical analysis**

Continuous data were displayed as mean ± standard deviation or median ± IQR for normal and non-normal distribution, respectively. The comparison of the study groups was made through two sample t-test or Mann–Whitney U-test, while categorical data were displayed as N (%) and compared using χ² or Fisher’s exact test. To measure the miRNAs expression, the Kruskal–Wallis H-test was used. However, correlation analysis was done by Spearman’s correlation coefficient between the miRNA expression and CD4, NEF, viral load and age. Moreover, false discovery rate was corrected by Benjamini–Hochberg approach for multiple comparisons. All statistical analyses were performed in STATA 14.2 (TX USA) and GraphPad Prism version 6 (CA, USA). Any p-value less than 0.05.

**Results**

A total of 106 cases (55 males and 51 females) and 32 healthy controls (male 15, female 17) were enrolled in our study which 87.7% (93/106) of samples were primary CNS tumors and the rest were metastatic CNS tumors. The mean age in the case group and control group were 46±17.6 (mean ± standard deviation) and 47.42±13.29 years, respectively. Of the four tumors with CNS metastasis, seven cases were diagnosed as adenocarcinoma (originating from lung cancer) and five cases were diagnosed as squamous cell carcinoma with the unknown primary site of origin. The primary CNS tumors samples in this study were categorized according to histopathologic criteria as follows: schwannoma (15/93, 14.1%), meningioma (13/93, 12.2%), and glioblastoma multiform (12/93, 11.3%). Histologically, astrocytoma, pituitary adenoma, epidermoid tumors, hemangioblastoma, pineoblastoma, oligodendroglioma, oligoastrocytoma, and chordoma, respectively, were the less common tumors. The mean of the WBC count was 8438.8±2645.5 cells per microliter (range, 3400-16700 WBC per microliter). More information was shown in Table 1.

EBV DNA was detected in 17% (18/106) of tumors tissue samples and 6.4% (2/32) of control tissues using the PCR method. In EBV positive tumors tissues, the most prevalence was in Astrocytoma (44.4%) and Glioblastoma multiforme (33.3%) had the highest prevalence of the EBV DNA. According to the results, statistically significant correlation was found between the presence of EBV and CNS tumors (p=0.001). In addition, the association between histopathological types of CNS tumors and EBV was not statistically significant (R=0.61). More details are presented in Table 3.

In the Table IV, Figure 1 and 2, the expression level of miR-122 was compared between CNS tumors tissues and healthy controls, also between EBV positive and EBV negative tissues. According to results, the expression level

![Figure 1](image1.png)

**Figure 1.** Comparison of the miR-122 Expression in Astrocytoma, Glioblastoma Multiforme, Meningioma and Schwannoma Tissue Samples. In astrocytoma and glioblastoma multiforme samples, the expression level of miR-122 in the EBV-positive group was significantly different from the EBV-negative group (*, P ≤ 0.05). The expression level of miR-122 was significantly downregulated in EBV-positive astrocytoma, glioblastoma multiforme, meningioma, and schwannoma, compared to the control group (**, P ≤ 0.01; ****, P ≤ 0.0001).
of miR-122 was upregulated in squamous cell carcinoma, Chordoma, Adenocarcinoma tissue samples compared to control samples, but the increase in expression was not significant (Table 4). Also, the expression level of miR-122 was significantly downregulated in astrocytoma, glioblastoma multiforme, meningioma, schwannoma, oligoastrocytoma, and hemangioblastoma tumors tissue samples than in normal tissues (Figures 1 and 2, p<0.05, Table 4). Besides, the expression level of miR-122 was not significantly different between groups in pineoblastoma, epidermoid tumors, and pituitary adenomas tissue samples (Figure 2, ns, p>0.05). Moreover, the results showed that the miR-122 was differentially expressed in histopathological type of CNS tumors (Table 4). Also, among all the samples, the highest reduction in the expression level of miR-122 was observed at astrocytoma

| Histopathology                        | N=106 | sex (M: F) (55:51) | Mean age (range) | Mean WBC counts per microliter (range) |
|---------------------------------------|-------|-------------------|-----------------|----------------------------------------|
| Schwannoma                            | 15 (14.1%) | 9:06              | 45.7 (25-56)    | 8151.4 (4500-10950)                     |
| Meningioma                            | 13 (12.2%) | 8:05              | 63.1 (49-83)    | 9067.5 (6190-14150)                     |
| Glioblastoma multiform                | 12 (11.3%) | 3:09              | 55.1 (20-74)    | 6838.5 (3400-9100)                     |
| Astrocytoma                           | 9 (8.5%) | 4:05              | 48.9 (18-67)    | 9596.6 (6800-11900)                     |
| Pituitary adenoma                     | (8.5%)9 | 6:03              | 54.3 (46-65)    | 8948.3 (7650-10450)                     |
| Epidermoid tumour                     | 7 (6.6%) | 5:02              | 39.2 (33-44)    | 11436.6 (6210-15490)                    |
| Adenocarcinoma (metastatic)           | 7 (6.6%) | 4:03              | 47.7 (39-60)    | 8960.0 (5400-16700)                     |
| Hemangioblastoma                      | 7 (6.6%) | 1:06              | 51.6 (48-54)    | 7985.0 (6620-8750)                     |
| Pineoblastoma                         | 6 (5.7%) | 3:03              | 12.9 (11-16)    | 7591.0 (6100-9300)                     |
| Oligodendroglialoma                   | 6 (5.7%) | 4:02              | 44.1 (25-56)    | 8051.4 (4500-10950)                    |
| Oligoastrocytoma                      | 5 (4.7%) | 2:03              | 60.1 (49-83)    | 8567.5 (6190-14150)                    |
| Chordoma                              | 5 (4.7%) | 2:03              | 56.9 (20-74)    | 6838.5 (3400-9100)                     |
| Squamous cell carcinoma (metastatic)  | 5 (4.7%) | 4:01              | 51.3 (18-67)    | 9090.0 (6800-11900)                    |

Table 1. Characteristics of Cases and Controls
Asian Pacific Journal of Cancer Prevention, Vol 22

Discussion

Brain tumors include 2% of all tumors in patients and glioma and meningioma are the most frequent types, however, its reason is yet unknown and needs further research (Bergo et al., 2016; Langen et al., 2017; Zavala-Vega et al., 2017a). Various molecular biology-based techniques indicate a link between viral infections and brain tumors but is not still clear which virus plays a major impact on brain tumorsigenesis and progression (Strojnik et al., 2017; Fonseca et al., 2015; Leibovitch et al., 2016; Zavala-Vega et al., 2017a; Akhtar et al., 2018b). In 1964, EBV was identified as the first human oncovirus which is one of the important risk factors in human cancers originating from lymphocytes, epithelial cells, and mesenchymal cells (Moghoojfei et al., 2019; Ko, 2015). In this study, we indicated that EBV infected 17.24% of tumors tissue samples and 6.4% of control tissues. According to the results, among the EBV-infected tumors samples, EBV-DNA had the highest prevalence in astrocytoma (4/9, 44.4%), and glioblastoma multiforme (4/12, 33.3%), respectively and in general, a statistically significant relationship was found between the presence of EBV and CNS tumors (p < 0.001). Leibovitch et al. investigated the relationship between some herpes viruses (EBV, HCV, and HHV-6A, B) and astrocytoma in 112 brain tissue specimens by using PCR (PCR) method. Although the HCMV and HHV-6A genomes were not detected in any of the samples, HHV-6B and EBV were detected in 13.3% and 8.9% of the astrocytoma samples, respectively. Only EBV was statistically positive in that study (Leibovitch et al., 2016). In the present study, the EBV genome was found in 44.4% of tissue samples of patients with astrocytoma.

Zavala-Vega et al., (2017b) investigated the rate of EBV, CMV and HSV 1/2 infection in the brain tissue of GBM patients by using in situ hybridization (ISH), real-time PCR, and immunohistochemistry (IHC). The mono-infection of CMV, HSV-1/2, and EBV were detected in 4.8%, 19%, and 28.6%, respectively. Furthermore, co-infection of CMV- EBV, HSV-1/2- EBV and also HSV-1/2-EBV- CMV were detected in 23.8%, 19%, and 43.4%, respectively. In the current study, we detected the EBV-DNA genome in all tissue samples of patients. Furthermore, Cosset et al., (2014) investigated the presence of VZV, EBV, HHV-6, HSV, CMV in 20 brain tumors biopsies. They reported that none of those viruses were detected in meningiomas, low-grade gliomas, oligoastrocytoma, oligodendroglioma, and ependymoma.

Unlike, in the current study, the EBV genome was found in meningioma (3/13, 23%) oligoastrocytoma (1/5, 20%) samples and similarly, the virus genome was not detected in any sample of oligodendroglioma tissue (Table 3).

In the study performed by Poltermann et al. (Poltermann et al., 2006) reported that IgG antibodies against EBV in the serum of 8.33 of patients with acoustic schwannomas and also, in our study, EBV was detected by PCR method in 20% tissue samples of patients with schwannomas. These differences may be due to the methods used to detect the virus (Further studies are shown in Table 6).

The first human virus known to encode viral-miRNAs was the EBV virus that encoding miR-BART1-3p (miR-BART 1 to miR-BART 22) and miR-BHRF1 (miR-BHRF1 to miR-BHRF3) (Barth et al., 2018).
Several studies shown that EBV actively uses its own miRNAs to regulate cellular and viral pathways during oncogenic transformation (Barth et al., 2011). Some studies have reported that EBV oncoproteins were not expressed in nasopharyngeal carcinoma (NPC) infected with EBV, so it may be possible that other mechanisms contribute to tumors progression. However, Chen et al., (2010) reported that three EBV-miRNAs including miR-BART9, 5 and 3 were overexpressed in all NPC tissues examined. In addition, EBV-BART9 leads to the upregulation of LMP1 mRNA levels and increases growth rates in Nasal NK T Cell Lymphomas (Ramakrishnan et al., 2011). In another study performed by Hsu et al., (2014) have been demonstrated which miR-BART9 through inhibiting of E-cadherin promotes the invasiveness and migration of NPC cells. For the first time, Ye et al., (2013) investigated gene expression profiles among metabolism-associated genes in NPC and EBV-miR-BART1 in by the RNA deep sequencing approach. They found that this miRNA is associated with the metabolism of NPC and maybe play critical roles in NPC development. It has been observed that miR-BART1 is upregulated in NPC cells and EBV-miR-BART1 causes promote tumors metastasis by regulating PTEN-dependent pathways in NPC. However, the role and expression level of miR-BART1 in brain tumors has not been well studied.

Table 3. Comparison of the Characteristics between EBV Positive and EBV Negative Cancer Tissues

|                      | EBV Positive | EV Negative | Total | P-value |
|----------------------|--------------|-------------|-------|---------|
| Number               | 18 (17%)     | 88 (83%)    | 106   | 0.56    |
| Age (years)          | 47±8 (20-83) | 45.0 ± 17.3 (11-47) | 46 ±17 (11-83) | 0.11    |
| WBC counts per microliter | 8947.3 ± 3301 | 8102.3 ± 2310.5 | 8514.8 ± 2461.5 | 0.155   |
|                      | (4920-16700) | (3390-15490) | (3610-16700) |         |
| Tumour Location      |              |             |       |         |
| Meninge              | 3 (2.84%)    | 15 (14.15%) | 18    | 0.11    |
| Brain                | 15 (14.15%)  | 73 (68.66%) | 88    |         |
| Gender               |              |             |       |         |
| Male                 | 8 (7.54 %)   | 47 (44.33%) | 55    | 1       |
| Female               | 10 (9.43%)   | 41 (38.67%) | 51    |         |
| Tumour Pathology     |              |             |       |         |
| Schwannoma           | 3 (20%)      | 12 (80%)    | 15 (14.15%) | 0.452  |
| Meningioma           | 3 (23%)      | 10 (77%)    | 13 (12.26%) |         |
| Glioblastoma multiform | 4 (33.3) | 8 (66.7%) | 12 (11.32%) |         |
| Astrocytoma          | 4 (44.4%)    | 5 (55.6%)   | 9 (8.5%) |         |
| Pituitary adenomas   | 1 (11%)      | 8 (89%)     | 9 (8.5%) |         |
| Epidermoid tumour    | 1 (14.28%)   | 6 (85.7%)   | 7 (6.6%) |         |
| Adenocarcinoma (metastatic) | - | 7 (100%) | 7 (6.6%) |         |
| Hemangioblastoma     | -            | 7 (100%)    | 7 (6.6%) |         |
| Pineoblastoma        | 1 (16.6%)    | 5 (83.4%)   | 6 (5.7%) |         |
| Oligodendrogloma     | -            | 6 (100%)    | 6 (5.7%) |         |
| Oligoastrocytoma     | 1 (20%)      | 4 (80%)     | 5 (4.7%) |         |
| Chordoma             | -            | 5 (100%)    | 5 (4.7%) |         |
| Squamous cell carcinoma (metastatic) | - | 5 (100%) | 5 (4.7%) |         |

Table 4. Comparison of the miR-122 Expression between CNS Tumour Tissues and Healthy Controls

| Tumour type          | Fold change *- | log2 | Expression level | P-value |
|----------------------|----------------|------|------------------|---------|
| Control              | 1              | 0    | Unchanged        | NA      |
| Astrocytoma          | 0.18           | -2.47±0.67 | Down             | <0/0001 |
| Glioblastoma multiform | 0.25 | -2±0.51 | Down             | <0/0001 |
| Meningioma           | 0.3            | -1.73±0.31 | Down             | <0/0001 |
| Schwannoma           | 0.38           | -1.39±0.31 | Down             | 0/0001  |
| Oligoastrocytoma     | 0.41           | -1.2±0.68  | Down             | 0.001   |
| Pineoblastoma        | 0.82           | -0.28±0.14 | Down             | ns      |
| Epidermoid tumour    | 0.88           | -0.18±0.15 | Down             | ns      |
| Pituitary adenomas   | 0.91           | -0.13±0.13 | Down             | ns      |

Table 5. Comparison of the miR-BART 1-3p Expression between EBV Positive Tissues and Healthy Controls

| Expression level | EBV+ cancer tissue (N = 18) | EBV+ Control tissue (N=2) | Fold Change | P-Value | Adjusted P-value |
|------------------|-----------------------------|---------------------------|-------------|---------|------------------|
| miR-BART1-3p     | 15.36 ± 0.35                | 7.15 ± 5.37               | 2.14        | <0.01   | 0.001            |
In this study, we assessed the miR-BART1-3p levels in EBV-positive tissue samples and results demonstrated that miR-BART1-3p level significantly increased in EBV positive tumors samples compared with the EBV-positive control samples ($p<0.01$). Also, this study is the first report of the expression level of miR-BART1-3p in human CNS tumors tissues.

Nowadays, because of the importance of miRNAs as a biomarker in the diagnosis of various disorders, including cancer and viral diseases, has received much attention (Nahand et al., 2019). Dysregulation of miRNAs is associated with different pathological cellular conditions such as cancer, viral infection, inflammation and etc. (Witwer, 2015). Thus, they can be used as important diagnostic biomarkers. For example, miR-122 has been reported to be associated with heart diseases and suggested that probably overexpression of this miRNA implicated in the proliferation and apoptosis of cardiomyocytes (Zhang and Jing, 2018). As well, it has reported which increased circulating miR-122 acts as a discrimination biomarker between sepsis and infection (Rahmel et al., 2018) and has potential as a new, predictive, and reliable marker for chemical, alcohol-, and viral-induced liver injury (Zhang et al., 2010). In addition, the miR-122 levels has been investigated in various cancer cell types and observed that acts as both a tumors suppressor in hepatocellular carcinoma (Zeisel et al., 2012), gastric cancer (Rao et al., 2017) breast cancer (Wang et al., 2012) and as an oncomiR (miRNA that is associated with cancer) in renal cell carcinoma (Jingushi et al., 2017). However, the function of this miRNA as oncomiR or tumors suppressor in CNS/brain cells is not yet fully understood. In the study conducted by the Wang and colleagues the miR-122 level was assessed in the normal group and

### Table 6. Prevalence of EBV in Brain Tumours

| Author            | Country | Sample (Number)                                    | Method                                | Detection result | Ref |
|-------------------|---------|---------------------------------------------------|---------------------------------------|------------------|-----|
| Neves et al. 2008 | Portugal| Tissue formalinfixed Pilocytic astrocytoma (n=35)  | Real time PCR                         | 9 (26%)          | 32  |
| Cimino et al. 2014| USA     | Tissue formalinfixed Highgrade glioma (n=21)      | NGS                                   | 5 (24%) Glioblastoma | 33  |
| Fonseca et al. 2015| Brazil  | Fresh tissue: astrocytoma grade1 (n=7), astrocytoma grade2 (n=25), astrocytoma grade3 (n=16), GBM (n=18), ependymoma (n=5), oligodendrogloma (n=2), oligoastroctoma (n=2) Total (n=75) | PCR | 11 (14.7%) Glioblastoma | 28  |
| Lin et al. 2016   | USA     | Tissue formalinfixed Glioblastoma multiform (n=19) | Multiplex droplet digital PCR         | 4 (21%)          | 27  |
| Strojnik et al. 2017| Slovenia | Fresh tissue glioma Grade (34) 45 | Real time PCR | 3 (6.7%) Glioblastoma | 8 |
| Zavalet et al. 2017| Mexico  | Tissue formalinfixed Glioblastoma multiform (n=21) | Immunohistochemistry In situ hybridization | 6 (28.6%) | 30  |
| Limam et al. 2019 | Tunisia | Tissue formalinfixed: pilocytic astrocytoma (n=12), glioma grade2 (n=6), glioma grade3 (n=6), GBM (n=82), Total (n=112) | PCR | 24 (21.4%) GBM | 34  |
| Khoury et al. 2013| USA     | Fresh tissue: Glioblastoma (n=168), Lowegrade glioma (n=47), Total (215) | RNA Sequencing None positive | 35 |
| Cosset et al. 2014| Switzerland | Fresh tissue and serum Glioblastoma multiform (n=20) | Semiquantitative PCR None positive | 36 |
| Hashida et al. 2015| Japan   | Tissue formalinfixed Glioblastoma multiform (n=35) | Real time PCR | None positive | 37  |
| Sanjiv et al. 2015| Canada  | Tissue formalinfixed Vestibular Schwannoma (n=121) | Immunohistochemistry None positive | 38  |
glioma patients. They demonstrated that the level of this miRNA was decreased in glioma patients compared to healthy subjects (Wang et al., 2014). In another study, Tang et al indicated that the miR-122 levels in the serum of glioma patients downregulated and levels of miR-122 could be used as a prognostic factor (Tang et al., 2017).

In the current study, a statistically significant difference between the levels of miR-122 in different tumors types (P=0.0001) was observed. Also, the expression level of miR-122 was downregulated in EBV positive tumors samples compare to the EBV negative samples (P<0.001). Notably that the greatest reduction in the expression level of miR-122 was in that of astrocytoma and GBM which these samples had the highest prevalence of EBV. It has been found that viruses by deregulation of miRNAs expression can alter cellular function to their advantage. In general, these results suggest that the miR-122 may act as a suppressor tumors in CNS and that the EBV infection can contribute to the progression of the tumors by dysregulation of miR-122 expression.

In summary, we demonstrated that the prevalence of EBV in CNS tumors was 17% and statistically, there is a significant relationship between the presence of EBV-DNA with CNS tumors. Also, the level of EBV-BART1-3p expression was significantly higher in EBV-positive tumors samples than EBV-positive normal samples. Besides, the expression level of miR-122 was significantly decreased in the EBV-positive sample compared to that of the EBV-negative sample. In general, the results of this study suggest that the EBV could change the condition of cancer cells by altering the expression of miR-122 and EBV-BART1-3p and maybe contribute to the development of cancer cells. These findings highlights the importance of the further investigations in this field.

Acknowledgements

Not applicable.

Funding

The current study was supported by grant no, 32677 from the research deputy of Iran University of Medical Sciences (IUMS).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

Mohammad Karimzadeh, “carried out the experiment and wrote the manuscript with support from results and discussion”

Alireza Tabibzadeh, “carried out the experiment and wrote the manuscript with support from results and discussion”

Mohsen Moghoofei, “conceived of the presented idea, verified the analytical methods, discussed the results and contributed to the final manuscript”

Saeedeh Abbasi, “wrote the manuscript with support from introduction and methods”

Javid Sadri Nahand, “performed the analytic calculations and performed the numerical simulations”

Farzin Sadeghi, “contributes to sample preparation”

Mohammad Hadi Karbalaei Niya, “contributes to sample preparation”

Javid Sadri Nahand, “conceived of the presented idea, verified the analytical methods, discussed the results and contributed to the final manuscript”

Maryam Eshghaei, “conceived and planned the experiments, developed the theory, supervised the project and discussed the results and contributed to the final manuscript”

All authors discussed the results and contributed to the final manuscript.

Ethics approval and consent to participate

This study was approved by the Ethical Committee of Iran University of Medical Sciences (Ethics approval number: IR.IUMS.FM.D.REC.1397.085). Before entering the study, all participants were verbally informed of the aim and signed the consent form freely, according to the Declaration of Helsinki.

Patient consent for publication

Before entering the study, all participants were verbally informed of the aim and signed the consent form freely, according to the Declaration of Helsinki.

Competing interests

The authors have indicated no potential conflicts of interest in this study. All authors are aware of and agree to the content of the manuscript.

References

Al J, Xie Z, Liu C, Huang Z, Xu J (2012). Analysis of EBNA-1 and LMP-1 variants in diseases associated with EBV infection in Chinese children. Virology, 9, 13.

Akhtar S, Vranic S, Cyprian FS, Mustafa A (2018). Epstein–Barr virus in gliomas: cause, association, or artifact?. Front Oncol, 5, 123.

Amon W, Farrell PJ (2005). Reactivation of Epstein–Barr virus from latency. Rev Med Virol, 5, 149-56.

Andrei G, Trompet E, Snoeck R (2019). Novel Therapeutics for Epstein–Barr Virus. Molecules, 24, 987.

Bandiera S, Pfeffer S, Baumert TF, Zeisel MB (2015). miR-122–a key factor and therapeutic target in liver disease. J Hepatol, 62, 448-57.

Barth S, Meister G, Grasser FA (2011). EBV-encoded miRNAs. Biochim Biophys Acta Gene Regul Mech, 1809, 531-40.

Bergo E, Lombardi G, Pambuku A, et al (2016). Cognitive rehabilitation in patients with gliomas and other brain tumors: state of the art. BioMed Res Int, 2016.

Bhattacharjee S, Bose P, Patel K, et al (2018). Transcriptional and epigenetic modulation of autophagy promotes EBV oncoprotein EBNA3C induced B-cell survival. Cell Death Disc, 9, 605.

Bhimrao SK, Maguire J, Garnis C, et al (2015). Lack of association between human herpesvirus and vestibular schwannoma: analysis of 121 cases. Otolaryngol Head Neck Surg, 152, 513-7.

Cai L, Ye Y, Jiang Q, et al (2015). Epstein–Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nat Commun, 6, 7353.

Chen S-J, Chen G-H, Chen Y-H, et al (2010). Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma
Zeisel M, Pfeffer S, Baumert T (2013). miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. *J Hepatol*, 58, 821-3.

Zhang J, Huang T, Zhou Y, et al (2018). The oncogenic role of Epstein–Barr virus-encoded micro RNA s in Epstein–Barr virus-associated gastric carcinoma. *J Cell Mol Med*, 22, 38-45.

Zhang X, Jing W (2018). Upregulation of miR 122 is associated with cardiomyocyte apoptosis in atrial fibrillation. *Mol Med Rep*, 18, 1745-51.

Zhang Y, Jia Y, Zheng R, et al (2010). Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. *Clin Chem*, 56, 1830-8.